Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 22;13(21):6311.
doi: 10.3390/jcm13216311.

Role of Lipoprotein(a) Reduction in Cardiovascular Disease

Uma Schuth  1 , Kieran Gill  2 , Pyotr Telyuk  3 , Bilal-Reshad Bawamia  4 , David Austin  3   5 , Azfar Zaman  6
Affiliations
Review

Role of Lipoprotein(a) Reduction in Cardiovascular Disease

Uma Schuth et al. J Clin Med. .

Abstract

Recent studies have shown that lipoprotein(a) (Lp(a)) is an important risk factor for a plethora of different cardiovascular diseases. It has been proven that Lp(a) levels are genetically determined and correlate with risk of cardiovascular disease, independent of lifestyle factors. As of yet, treatment options to reduce Lp(a) levels are limited, but new research into Lp(a) reduction yields promising results. This review delves into Lp(a)'s biochemistry and mechanism of effect, the association between Lp(a) and cardiovascular diseases, and possible therapies to minimise cardiovascular disease.

Keywords: atherosclerosis; cardiovascular disease; lipoprotein(a).

PubMed Disclaimer

Conflict of interest statement

David Austin reports receiving speaker fees from Astra Zeneca and Pfizer; research grants were awarded to Newcastle University from TA Sciences, Kancera, and Astra Zeneca. AZ reports receiving speaker fees from Amarin, Amgen, Sanofi, Astra Zeneca, Boehringer, Pfizer, Daiichi, and Napp. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure A1
Figure A1
The role of lipoprotein(a) in cardiovascular disease.
Figure 1
Figure 1
Lipoprotein(a) (Lp[a]) particle containing apolipoprotein B100 and apolipoprotein(a).
See this image and copyright information in PMC

References

    1. Utermann G. The mysteries of lipoprotein(a) Science. 1989;246:904–910. doi: 10.1126/science.2530631. - DOI - PubMed
    1. Berg K. A new serum type system in man-the lp system. Acta Pathol. Microbiol. Scand. 2009;59:369–382. doi: 10.1111/j.1699-0463.1963.tb01808.x. - DOI - PubMed
    1. Lackner C., Cohen J.C., Hobbs H.H. Molecular definition of the extreme size polymorphism in apolipoprotein(a) Hum. Mol. Genet. 1993;2:933–940. doi: 10.1093/hmg/2.7.933. - DOI - PubMed
    1. Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis. 2022;349:123–135. doi: 10.1016/j.atherosclerosis.2022.04.008. - DOI - PubMed
    1. Kraft H.G., Arno Lingenhel Silvano Köchl Hoppichler F., Kronenberg F., Abe A., Mühlberger V., Schönitzer D., Utermann G. Apolipoprotein(a) Kringle IV Repeat Number Predicts Risk for Coronary Heart Disease. Arterioscler. Thromb. Vasc. Biol. 1996;16:713–719. doi: 10.1161/01.ATV.16.6.713. - DOI - PubMed

LinkOut - more resources